Jefferies & Company Reports on Incyte

Jefferies & Company commented on Incyte INCY in a report released yesterday. In the report, Jefferies & Company was positive in its assessment of the company. Jefferies & Company writes, "INCY released new detail from the COMFORT-2 European study of ruxolitinib in myelofibrosis. On the primary endpoint, 28.5% of MF patients treated with ruxolitiniib experienced a 35+% reduction in spleen size at week 48 compared to 0% in the arm receiving best available therapy (BAT, p<0.0001). These rates are lower than observed in COMFORT-1 (41% at week 24), but we do not believe that the efficacy data are materially different, and in fact, we learned that the median spleen size reduction in both trials is very close (33% for COMFORT-1 vs. 29% for COMFORT-2). We remain positive on ruxolitinib's efficacy profile." Jefferies & Company currently has a Buy rating on Incyte. Shares of the company closed at 16.90 on Monday, up $0.39 from the opening bell.